Despite these encouraging trends, the market has hurdles, including due to the high cost of GLP-1 agonists, which may limit access for specific patient populations
They are not independently verified by this publication, may not represent typical outcomes, and should not be interpreted as guarantees of weight loss, medication eligibility, side-effect profile, prescription approval, or health outcomes
You may be eligible for compounded semaglutide if branded Ozempic or Wegovy are on the FDA shortage list 4
N Engl J Med 377(3):300301
32 Since tirzepatide does not have a GIP (3142) tail, chosen Ala 21 was likely to increase the GLP-1 activity, despite it slightly decreasing the GIP activity
Amin RS, Simakajornboon N, Szczesniak RV